Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 8/20 | 0.34 |
| ▸ | IAPP | P10997 | 1/20 | 0.34 |
| ▸ | TYR | P14679 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1022386 | 1.00 | LMNA (0.36) | LMNAMAPK1APPMGLLIAPP | |
| SCHEMBL1021072 | 0.88 | MGLL (0.46) | LMNAMAPK1MGLL | |
| SCHEMBL1021071 | 0.88 | MGLL (0.46) | LMNAMAPK1MGLL | |
| SCHEMBL1021645 | 0.84 | CNR1 (0.36) | LMNAMAPK1 | |
| SCHEMBL1021646 | 0.84 | CNR1 (0.36) | LMNAMAPK1 | |
| SCHEMBL1021272 | 0.83 | GCGR (0.36) | LMNAMAPK1MGLL | |
| SCHEMBL1022051 | 0.83 | MGLL (0.40) | LMNAMAPK1MGLLTYR | |
| SCHEMBL1021271 | 0.83 | GCGR (0.36) | LMNAMAPK1MGLL | |
| SCHEMBL1021263 | 0.83 | MAPK1 (0.35) | LMNAMAPK1 | |
| SCHEMBL1022053 | 0.83 | MGLL (0.40) | LMNAMAPK1MGLLTYR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8013187-B2 | 2-cyclopenten-1-one oxime derivatives inhibiting production of TNF-α | AMOREPACIFIC CORPORATION (KR) | 2011-09-06 | — | — | US | claimed |
| EP-1841729-B1 | 2-CYCLOPENTEN-1-ONE OXIME DERIVATIVES INHIBITING PRODUCTION OF TNF-ALPHA | AMOREPACIFIC CORP (KR) | 2011-01-12 | — | — | EP | claimed |
| US-20090036501-A1 | 2-Cyclopenten-1-One Oxime Derivatives Inhibiting Production of TNF-Alpha | AMOREPACIFIC CORPORATION (KR) | 2009-02-05 | — | — | US | claimed |
| US-8013187-B2 | 2-cyclopenten-1-one oxime derivatives inhibiting production of TNF-α | AMOREPACIFIC CORPORATION (KR) | 2011-09-06 | — | — | US | disclosed |
| EP-1841729-B1 | 2-CYCLOPENTEN-1-ONE OXIME DERIVATIVES INHIBITING PRODUCTION OF TNF-ALPHA | AMOREPACIFIC CORP (KR) | 2011-01-12 | — | — | EP | disclosed |
| US-20090036501-A1 | 2-Cyclopenten-1-One Oxime Derivatives Inhibiting Production of TNF-Alpha | AMOREPACIFIC CORPORATION (KR) | 2009-02-05 | — | — | US | disclosed |
| EP-1841729-A1 | 2-CYCLOPENTEN-1-ONE OXIME DERIVATIVES INHIBITING PRODUCTION OF TNF-ALPHA | Amorepacific Corporation (KR) | 2007-10-10 | — | — | EP | disclosed |
| WO-2006059867-A1 | 2-CYCLOPENTEN-1-ONE OXIME DERIVATIVES INHIBITING PRODUCTION OF TNF-ALPHA | AMOREPACIFIC CORPORATION (KR) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036501-A1 | 2-Cyclopenten-1-One Oxime Derivatives Inhibiting Production of TNF-Alpha | TNF, PDE4A, PDE3B | LMNA 4341/4885MAPK1 153/4885APP 2058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.